D C Talbot

PROGNOSTIC VALUE OF ANGIOGENESIS IN OPERABLE NON-SMALL CELL LUNG CANCER

Alexandra Giatromanolaki, Michael Koukourakis, Kenneth J. O’Byrne et al. · The Journal of Pathology · 1996 · 170 citations

Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions.

Valentine M. Macaulay, Kenneth J. O’Byrne, Mark Saunders et al. · PubMed · 1999 · 160 citations

Intrapleural Bb-94, Matrix Metalloproteinase Inhibitor, Intrapleural Administration +16

Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer.

N C Levitt, Ferry A.L.M. Eskens, Kenneth J. O’Byrne et al. · PubMed · 2001 · 136 citations

Tumor Response, Chemoprevention Strategy, Pharmacological Study +14

Anthrapyrazole CI941: a highly active new agent in the treatment of advanced breast cancer.

D C Talbot, Ian E. Smith, Janine Mansi et al. · Journal of Clinical Oncology · 1991 · 62 citations

World Health Organization, Breast Oncology, Cancer Management +17

Phase I/II study of gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer: preliminary results.

W.P. Steward, Dunlop Dj, G Dabouis et al. · PubMed · 1996 · 58 citations